Scotland’s life sciences sector — a £7.0 billion industry already targeted to reach £25 billion by 2035 under a Scottish Government strategy that will stand up a new AI Scotland agency this year — has its competitive benchmark for the next phase set today, and it is not being set in Scotland. Bristol Myers Squibb (NYSE: BMY) and Anthropic announced this afternoon a strategic agreement that places Anthropic’s Claude in front of more than 30,000 BMS employees, across research, clinical development, manufacturing, commercial and corporate functions at one of the world’s largest biopharmaceutical groups.
The deal puts agentic AI — software that takes actions, not just answers questions — at enterprise scale inside a regulated global biopharma. It is one of the largest single commitments of its kind disclosed publicly in the life sciences sector to date. The terms of the agreement were not disclosed. BMS said the rollout would build on more than three years of internal AI investment, during which the company had given staff access to leading frontier models through a proprietary internal platform on a deliberately multi-vendor basis. The Anthropic agreement positions Claude Enterprise as the shared intelligence layer above that platform.
Eric Kauderer-Abrams, Head of Life Sciences at Anthropic, said the goal was to create “a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time.” Greg Meyers, Chief Digital and Technology Officer at BMS, framed the move as a move beyond the chatbot era: “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos.”
The deployment focuses on three priorities: standardising engineering and data science work on Claude Code; embedding agents into research, drug development, manufacturing and commercial workflows; and connecting Claude to the internal repositories where BMS’ scientific, regulatory and clinical knowledge resides, under enterprise governance and audit controls.
The Scottish reading is comparator-focused. Scotland’s £7.0 billion life sciences turnover, the latest figure reported in the UK government’s Life Sciences Sector Plan, makes it one of the largest regional life sciences clusters outside the South East of England. In November 2025, the Scottish Government set the £25 billion life sciences target by 2035 and confirmed the launch of AI Scotland to accelerate AI adoption across public and private sector life sciences activity from 2026.
Named Scottish institutions are already working at the AI / drug discovery boundary. The University of Dundee’s Drug Discovery Unit, founded in 2006 and now an 18-year-old translational drug discovery centre with four compounds in or through clinical trials, has been applying machine learning to small-molecule design through external partnerships since 2021. Edinburgh BioQuarter, Glasgow’s biotech cluster and the wider University of Strathclyde life sciences activity make up an ecosystem that is well-positioned in research terms but, as the UK Sector Plan itself notes, has historically struggled to capture commercial value from its scientific output.
The BMS-Anthropic agreement re-sets what enterprise-scale AI integration in life sciences looks like in practical terms. It is not a research collaboration or a single-use pilot. It is a company-wide commitment to agentic AI as the connective tissue between research, development, manufacturing and commercial activity at one of the world’s largest biopharmaceutical groups. That sets a competitive marker for Scottish life sciences companies and for AI Scotland as it ramps up — the question is no longer whether to embed AI, but whether Scottish firms can move at the pace and scale that today’s announcement implies.
The Scottish ambition is in place. The infrastructure thesis, between AI Scotland and the Lanarkshire AI Growth Zone, is in place. The next twelve months will test whether Scottish life sciences can translate ambition into deployed agentic systems at a comparable scale, or whether the gap between Scottish research strength and Scottish commercial AI deployment widens.
